# Escalated Dose of Irinotecan in mCRC

> **NCT02256800** · NA · COMPLETED · sponsor: **Jaw-Yuan Wang, MD, PhD** · enrollment: 213 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **GENETIC:** UGT1A1 genotyping (6,6)
- **GENETIC:** UGTIA1 genotyping (6,7)
- **GENETIC:** UGTIA1 genotyping (7,7)
- **GENETIC:** UGT1A1 non-genotyping
- **DRUG:** bevacizumab (Avastin)
- **DRUG:** irinotecan
- **DRUG:** Leucovorin
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT02256800
- **Lead sponsor:** Jaw-Yuan Wang, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-13
- **Primary completion:** 2017-11-30
- **Final completion:** 2017-11-30
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2021-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256800, "Escalated Dose of Irinotecan in mCRC". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT02256800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*